Core Viewpoint - A class action lawsuit has been filed against Cytokinetics, alleging securities fraud and unlawful business practices related to the company's New Drug Application for aficamten [1]. Summary by Relevant Sections Class Action Details - Investors are encouraged to contact Pomerantz LLP to join the class action, with a deadline to appoint a Lead Plaintiff by November 17, 2025 [1]. - The lawsuit centers on whether Cytokinetics and its officers engaged in fraudulent activities concerning their securities [1]. FDA Interaction and Stock Impact - On March 10, 2025, Cytokinetics announced that the FDA would not hold an advisory committee meeting for aficamten's NDA [1]. - The FDA extended the action date for aficamten's NDA from September 26, 2025, to December 26, 2025, due to the need for a Risk Evaluation and Mitigation Strategy (REMS) that was not included in the original NDA [1]. - Following this announcement, Cytokinetics' stock price dropped by $5.57, or 12.98%, closing at $37.35 on May 2, 2025 [1]. - On May 6, 2025, CEO Robert I. Blum revealed that the company had multiple pre-NDA meetings with the FDA but chose to submit the NDA without a REMS, leading to a further stock price decline of $2.70, or 7.36%, closing at $33.97 [1].
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Cytokinetics, Incorporate of Class Action Lawsuit and Upcoming Deadlines - CYTK